NCT02919345View on ClinicalTrials.gov

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery

PHASE4CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

March 31, 2019

Conditions
Diabetes Mellitus, Type 2Coronary Artery DiseaseCarotid Artery Diseases
Interventions
DRUG

Dapagliflozin 10 mg

Dapagliflozin 10 mg in addition to Metformin 1500 mg/day

DRUG

Glibenclamide 5 mg

Glibenclamide 5 mg in addition to Metformin 1500 mg/day

Trial Locations (1)

13083-887

State University of Campinas, Campinas

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Campinas, Brazil

OTHER